Bilateral episcleritis as a manifestation of cutaneous leukocytoclastic vasculitis.
OBJECTIVE
The authors describe how bilateral episcleritis can be a sign of active systemic disease and can respond to treatment in a patient with cutaneous leukocytoclastic vasculitis.


METHODS
Case report.


METHODS
Comprehensive ophthalmic and physical examination and color photography were used to monitor inflammation and its response to systemic immunosuppression.


RESULTS
Systemic cyclophosphamide caused regression of systemic symptoms, cutaneous lesions, and episcleritis. After an 8-month follow-up, the patient has not had a systemic or ocular recurrence.


CONCLUSIONS
Episcleritis may be a manifestation of cutaneous leukocytoclastic vasculitis. Careful examination of ocular inflammation is important in monitoring systemic disease and treatment.
Bollinger
K
K
Cleveland Clinic Foundation, Cole Eye Institute, Cleveland, Ohio, USA.
Medina
C
C
Perez
V L
VL
D000368:Aged; D003520:Cyclophosphamide / Q000627:therapeutic use; D007839:Functional Laterality; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D015423:Scleritis / Q000175:diagnosis* / Q000188:drug therapy; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000175:diagnosis* / Q000188:drug therapy
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate